Abstract
Heterogeneity in the mechanisms of coagulation may contribute to an increased thrombotic risk for patients with malignancies. The coincidence of malignancies and antiphospholipid antibodies (aPL) have been described in several important epidemiological studies. The pathological significance of aPL in patients with malignancies is, however, still unclear. In this study, we investigated the clinical manifestations of four patients with elevated IgM-aPL titres lying outside the region signifying 95% of normal cases and with a history of non-Hodgkin’s lymphoma. The patients had elevated IgG- and IgM-anticardiolipin antibodies (aCL) and also tested positive for lupus anticoagulants. Other aPL were measured, and we found high positive results for all tested antibodies in three patients. The production of aPL, however, occurred in the absence of thrombotic complications. No thromboembolic manifestations occurred during the follow-up period either. It could also be demonstrated that the degree to which the aCL titre was elevated resembles the elevation of the non-classical antiphospholipid antibodies, but not that of β2-GP-1 or anti-annexin antibodies. Therefore, it can be postulated that these extremely high levels of IgM-aCL antibodies do not enhance the risk of thrombosis and may be completely different from aCL antibodies in an antiphospholipid syndrome patient population without malignancies. In particular, haematological and lymphoproliferative malignancies may indeed be associated with the generation of aPL, but do not necessarily enhance the thrombophilic risk in these patients.
References
Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311
Asherson RA (2000) Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun 15:117–122
Pusterla S, Previtali S, Marziali S et al (2004) Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 5:341–346
Shoenfeld Y, Blank M, Sherer Y (2001) Induction and treatment of the antiphospholipid sydnrome—lessons from animal models. Eur J Clin Invest 31:736–740
Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269–275
Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185–1190
Miesbach W, Matthias T, Scharrer I (2005) Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci 1050:250–256
Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, Alam Z, Carey JL (1997) IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28:1660–1665
Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832
Shepshelovich D, Shoenfeld Y (2006) Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 15(3):183–190
Lossos IS, Bogomolski-Yahalom V, Matzner Y (1998) Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol 57:139–143
Schved JF, Dupuy-Fons C, Biron C et al (1994) A prospective epdimiological study of the occurrence of antiphospholipid antibody; the Montpelier Antiphospholipid (MAP) Study. Haemostasis 24:175–182
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miesbach, W., Scharrer, I. & Asherson, R.A. High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma. Clin Rheumatol 26, 95–97 (2007). https://doi.org/10.1007/s10067-006-0328-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0328-9